Here's Why Marinus Pharmaceuticals Is Soaring Today

Welcome to the popular clique, kid. Shares of clinical-stage biopharma Marinus Pharmaceuticals (NASDAQ: MRNS) rose as much as 22.2% by noon EST after the company announced it will be added to the coveted NASDAQ Biotechnology Index on Dec. 18. The index includes biopharma and (oddly) pharmaceutical companies that meet certain eligibility requirements such as a minimum market cap. The NASDAQ Biotechnology Index is adjusted annually, and this year Marinus Pharmaceuticals made the cut.

BING NEWS:
  • Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?
    Marinus Pharmaceuticals (NASDAQ:MRNS) stock is taking a beating on Monday after the pharmaceutical company announced results from a Phase 3 clinical trial. It’s bad news for MRNS stockholders ...
    04/15/2024 - 4:36 am | View Link
  • Marinus Pharmaceuticals' Trial of Therapy For Persistent Seizures Misses Early Stopping Criteria
    Marinus Pharmaceuticals said its phase 3 trial evaluating a therapy for a condition that causes persistent seizures didn't meet early stopping criteria at its interim analysis. The stock was ...
    04/15/2024 - 12:27 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News